Boosting organ-on-chip technologies for lung cancer research: Tumor-LN-oC issues first press release

Lung cancer is a leading cause of death accounts for 1/5 of total cancer deaths. It is believed that up to 70% of metastases occurs through the lymphatic system with lymphatic vessels and lymph nodes (LN) mediating the process. This is the starting point of the Horizon2020-funded Tumor-LN-oC project, which unites 11 universities, institutions and SMEs from 9 European countries.

The project kicked off in May 2021 and is progressing steadily. In this context, it is our pleasure to share that the consortium just published its first press release. It contains more information on the launch of the project, as well as its objectives and expected impact, and is publicly available here: https://tumor-ln-oc.eu/wp-content/uploads/2021/09/Tumor-LN-oC-press-release.pdf

Tumor-LN-oC aims to offer a comprehensive solution for a robust, automated tumor-lymph node-on-chip platform that will connect primary surgically removed human tumors and LN tissue from the same cancer patient. This will allow to study the interaction of primary tumors with lymph nodes, identify their chemical signature, and offer personalized treatment relying on molecular characterization of lymph node metastasizing cells. Thereby, the project will significantly advance the fields of microfluidics, cell biology, cancer biology, physics, and computer programming and software development.

For more information, we invite you to visit the project website and encourage to use the contact form to get in touch with us – we’re looking forward to seeing you over at https://tumor-ln-oc.eu/ !